CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.
The interim results of a phase 1b/2 trial showed that patients with soft tissue sarcoma and lung metastases who were treated with annamycin experienced positive clinical activity.
BXCL701 and pembrolizumab may resolve the need for FDA-approved therapies for patients with small cell neuroendocrine prostate cancer, according to investigators.
In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
After reviewing the case of a patient with transplant-eligible newly-diagnosed multiple myeloma, experts consider optimal selection of first-line treatment.
Practical considerations regarding the role of NRG1 fusions in lung cancer management and how that has been informed by the eNRGy1 global registry study.
A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.
Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.
Key takeaways from a paper that evaluated the efficacy of tipifarnib in recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.
An overview of what is currently understood about the use of ctDNA assays to help guide treatment decisions when managing patients with colorectal cancer undergoing resection of metastases.